论文部分内容阅读
目的:探讨前列倍喜胶囊加а-受体阻滞剂(naftopidil)治疗慢性前列腺炎/慢性骨盆疼痛综合征(CP/CPPS)的临床疗效。方法:按前列腺炎诊断治疗指南标准[1]选出符合CP/CPPS患者96例,采用随机双盲对照,分为治疗组和对照组。治疗组(56例)服用前列倍喜胶囊加а-受体阻滞剂;对照组(40例)服用а-受体阻滞剂加安慰剂;疗程为6周。配合前列腺按摩,每周一次,然后观察其疗效。结果:治疗组56例患者,显效16例,有效34例,无效6例。总有效率89.3%(50/56);对照组40例患者,显效4例,有效24例,无效12例。总有效率70.0%(28/40)。两组疗效比较有统计学意义(P<0.05);治疗组治疗前后NIH-CPSI各项指标比较有显著性统计学意义(P<0.01);对照组治疗前后NIH-CPSI各项指标比较有统计学意义(P<0.05),两组治疗前后NIH-CPSI比较有统计学意义(P<0.05)。结论:前列倍喜胶囊加а-受体阻滞剂联合治疗CP/CPPS安全有效。
Objective: To investigate the clinical efficacy of Qianliexixi capsule combined with а-receptor blocker (naftopidil) in the treatment of chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS). Methods: Ninety-six patients with CP / CPPS were selected according to the guidelines for the diagnosis and treatment of prostatitis [1]. The patients were randomly divided into treatment group and control group. The treatment group (56 cases) was treated with Qianliexixi capsules plus а-blockers; the control group (40 cases) with а-receptor blockers plus placebo; course of treatment for 6 weeks. With prostate massage, once a week, and then observe its efficacy. Results: The treatment group of 56 patients, markedly effective in 16 cases, effective in 34 cases, 6 cases. The total effective rate was 89.3% (50/56). In the control group, 40 patients were markedly effective in 4 cases, effective in 24 cases and ineffective in 12 cases. The total effective rate 70.0% (28/40). The therapeutic effects of the two groups were statistically significant (P <0.05). The indexes of NIH-CPSI before and after treatment in the treatment group were statistically significant (P <0.01). The indexes of NIH-CPSI before and after treatment in the control group were statistically significant (P <0.05). NIH-CPSI before and after treatment in both groups was statistically significant (P <0.05). Conclusion: Qianliexixi capsule plus а-receptor blockers combined with CP / CPPS safe and effective.